The effects of boron nitride/hydroxyapatite compounds on bone defects in osteoporotic rats

TOPÇU A., HALICI Z., ÇADIRCI E., Karakus E., DOĞAN A., BAKAN F., ...Daha Fazla

JOURNAL OF MOLECULAR STRUCTURE, cilt.1295, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1295
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1016/j.molstruc.2023.136683
  • Dergi Adı: JOURNAL OF MOLECULAR STRUCTURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core, Chimica, Compendex, INSPEC
  • Anahtar Kelimeler: Bone defect, Boron nitride, Hydroxyapatite, Osteoporosis, PLGA, Rat, RESISTANT ACID-PHOSPHATASE, POPULATION-BASED COHORT, ALPHA-LIPOIC ACID, IN-VITRO, GENE-EXPRESSION, MORPHOGENETIC PROTEIN-2, MINERAL DENSITY, OSTEOPONTIN, OVARIECTOMY, ESTROGEN
  • Atatürk Üniversitesi Adresli: Evet

Özet

This study investigated the effects of poly-(lactide-co-glycolide) (PLGA) scaffolds containing different concentrations of boron nitride (BN) and/or hydroxyapatite (HA) on bone defects in osteoporotic rats. The control group consisted of healthy rats. A standard non-critical size defect was induced in the osteoporotic rat femurs 12 weeks post-ovariectomy. PLGA scaffolds containing different concentrations of BN+HA were then applied to the defect area. In one group, defect was induced but no PLGA was applied. Computed tomography images were obtained and tissue samples were collected in the first, second, and fourth weeks postoperatively. PLGA scaffolds were classified as no BN + HA, only 10% HA, 2.5% BN + 10% HA, 5% BN + 10% HA, 10% BN + 10% HA or only 2.5%, 5% or 10% BN. No healing was determined in the first and second weeks postoperatively. However, in the fourth week healing was observed in the groups treated with PLGA scaffolds containing 10% HA, 2.5% BN + 10% HA, 2.5% BN and 5% BN, and especially in the 2.5% BN + 10% HA group. The findings of this study suggest that BN may represent a novel target for treating osteoporotic bone defects for physicians and engineers.